Welcome Back
Join CoinTime
Sign in with email
Sign up with email
Check your inbox
UniQure
About
uniQure is focused on the research and early development of human gene-based therapies.
- Amsterdam,Noord-Holland,The Netherlands
- 101 - 250
- http://www.uniqure.com
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $20M
- Industries
- Biotechnology,Genetics,Health Care,Medical
- Founded date
- Nov 1, 2012
- Number Of Employee
- 101 - 250
- Operating Status
- Active
- Stock Symbol
- nasdaq:QURE
- Legal Name
- uniQure N.V.
uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.Our first product, Glybera, was approved by the European Commission in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease.We are also developing a pipeline of additional adeno-associated virus (AAV)-based gene therapies through multiple collaborations. We develop our gene therapies using our innovative, modular technology platform, including our proprietary manufacturing process. We initially are focused on orphan diseases but believe that we will also be able to develop gene therapies targeting chronic and degenerative diseases that affect larger populations.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 14, 2015 | Post-IPO Equity | $89M | — | — | — | Detail |
| Jul 1, 2014 | Post-IPO Debt | $20M | 1 | — | — | Detail |
| Feb 6, 2014 | IPO | $88.50M | — | — | — | Detail |
| Jul 9, 2013 | Private Equity（PE） | $58M | 3 |
Coller Capital
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Coller Capital
|
Yes | Private Equity（PE） |
Hercules Capital
|
— | Post-IPO Debt |
Chiesi Pharmaceuticals
|
— | Private Equity（PE） |
Forbion Capital Partners
|
— | Private Equity（PE） |
Employee Profiles
Acquisition
UniQure has acquired 2 organizations. Their most recent acquisition was InoCard on Aug 12, 2014. They acquired InoCard for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Aug 12, 2014
|
Biotechnology | acquisition | — | Detail |
|
Jun 23, 2021
Corlieve Therapeutics
|
Biotechnology | acquisition | € 46.30M | Detail |
